Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosusopen access
- Authors
- Urowitz, M.; Gladman, D. D.; Ibanez, D.; Sanchez-Guerrero, J.; Bae, Sang Cheol; Gordon, C.; Fortin, P. R.; Clarke, A.; Bernatsky, S.; Hanly, J. G.
- Issue Date
- Sep-2014
- Publisher
- WILEY-BLACKWELL
- Citation
- ARTHRITIS CARE & RESEARCH, v.66, no.9, pp.1374 - 1379
- Indexed
- SCIE
SCOPUS
- Journal Title
- ARTHRITIS CARE & RESEARCH
- Volume
- 66
- Number
- 9
- Start Page
- 1374
- End Page
- 1379
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/25773
- DOI
- 10.1002/acr.22299
- ISSN
- 2151-464X
- Abstract
- Objective. The Medical Outcomes Study Short Form 36 (SF-36) is recommended to assess quality of life (QOL) in systemic lupus erythematosus (SLE). The aim of the current study was to assess QOL over time in the first 5 years of a multicenter inception cohort of patients with SLE.
Methods. An inception SLE cohort was assembled according to a standardized protocol between 2000 and 2012. In addition to clinical and laboratory assessments, patients completed the SF-36 at yearly intervals. Only patients who had ˃= 5 completed QOL questionnaires were included in these analyses. Generalized estimating equation models were run separately for each of the 8 subscales and for the physical and mental component summary scores, adjusting for repeated measures by patients.
Results. A total of 495 patients were included. The mean +/- SD disease duration at the first visit was 5.3 +/- 4.1 months. The mean +/- SD age at enrollment was 35.8 +/- 13.2 years. All 8 subscales and the 2 summary scores showed improvement in the first 2 years from enrollment. Between years 2 and 5, none of the subscales or summary scores showed any change. Minimum clinically important improvement was achieved by 35-56% of the patients and was influenced by demographic and disease factors.
Conclusion. Unlike late-stage lupus, where QOL is stable over time, in patients with early disease, all subscales improve in early followup up to 2 years. Therefore, the SF-36 may be a sensitive outcome measure in early disease in patients with SLE.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/25773)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.